Business Context and Reporting Period
Artelo Biosciences, Inc. (Nasdaq: ARTL) filed a Current Report on Form 8-K on June 24, 2025, regarding a material definitive agreement entered into on the same date. The Company is a Nevada corporation headquartered in Solana Beach, California.
Key Financial Metrics and Transaction Details
The Company executed a private placement securities purchase agreement with accredited investors. The transaction structure includes:
- Common Stock: 136,843 shares at $5.82 per share.
- Pre-Funded Warrants: 93,180 warrants exercisable at $0.001 per share.
- Warrants: 460,046 warrants exercisable at $5.82 per share and 230,023 warrants exercisable at $10.00 per share.
- Pricing: Combined purchase price of $6.195 per share (plus warrants) or $6.194 per pre-funded warrant (plus warrants).
- Gross Proceeds: Approximately $1.425 million initially, with potential proceeds up to approximately $6.403 million if all warrants are fully exercised for cash.
- Closing Date: Expected June 26, 2025.
Material Changes and Use of Proceeds
This filing represents a new capital raise event rather than a change in historical financial performance. The Company intends to utilize the net proceeds as follows:
- Digital Currency Investment: Commercially reasonable efforts will be made to use $250,000 of net proceeds to purchase the digital currency known as SOL.
- General Corporate Purposes: The balance of the net proceeds will be used for general corporate and working capital purposes.
Guidance, Risks, and Contingencies
The filing outlines specific terms and limitations regarding the securities issued:
- Exercise Terms: Pre-funded warrants are exercisable immediately. The $5.82 and $10.00 warrants have a five-year term from the closing date.
- Beneficial Ownership Limitation: Holders may not exercise warrants if it results in beneficial ownership exceeding 4.99% or 9.99% (at the holder's election) of outstanding shares immediately post-exercise.
- Registration Rights: The Company agreed to file a registration statement within 15 days of closing to register the resale of shares and warrant shares.
- Exemptions: The offering is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received on or after June 26, 2025.
- Confirm the execution of the $250,000 purchase of SOL digital currency as planned.
- Review the filed registration statement (expected within 15 days of closing) for the resale of the new securities.
- Monitor the Company's cash position and working capital runway following the receipt of proceeds.
- Assess the potential dilution impact if the $5.82 and $10.00 warrants are exercised in the future.